In vivo, we administered pErNP–OVA–CpG B nanovaccine or control complexes subcutaneously, and then administered ErNP–aCD8 and QD–OVA–tetramer probes intravenously to target antigen-specific CD8+ CTLs residing in the tumour microenvironment through the blood. Here, CD8A is linked to neoplasm.